Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2024.02.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Philippe Sultanik und 11 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hypertension, Portal, Bevacizumab. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France.
- AP-HP Sorbonne Paris Nord, Hôpitaux Universitaire Paris Seine Saint-Denis, Service d'Hépatologie, Bobigny, France; INSERM UMR 1138, Centre de recherche des Cordeliers, 75006 Paris, France.
- AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service de radiologie interventionnelle, Paris, France.
- AP-HP Sorbonne Paris Nord, Hôpitaux Universitaire Paris Seine Saint-Denis, Service d'Hépatologie, Bobigny, France.
- AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service de radiologie diagnostique, Paris, France.
- AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France; Sorbonne Université, INSERM, Centre de recherche Saint-Antoine (CRSA), Institute of Cardiometabolism…
Zitieren
APA
Sultanik, P., Campani, C., Larrey, E., Campion, B., Evain, M., Roux, C., Blaise, L., Wagner, M., Rudler, M., Nault, J. C., Thabut, D., & Allaire, M. (2024). Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.02.018
Vancouver
Sultanik P, Campani C, Larrey E, Campion B, Evain M, Roux C, et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.02.018
BibTeX
@article{Sultanik2024,
author = {Sultanik, Philippe and Campani, Claudia and Larrey, Edouard and Campion, Bertille and Evain, Manon and Roux, Charles and Blaise, Lorraine and Wagner, Mathilde and Rudler, Marika and Nault, Jean Charles and Thabut, Dominique and Allaire, Manon},
title = {Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2024.02.018}
}
EUVIMED